- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT05565378
Fase 2-platformstudie van nieuwe immunotherapiecombinaties bij deelnemers met niet eerder behandelde, gevorderde/gemetastaseerde niet-kleincellige longkanker
Een fase 2, gerandomiseerde, open-label, platformstudie waarbij gebruik wordt gemaakt van een masterprotocol om nieuwe immunotherapiecombinaties te evalueren bij deelnemers met niet eerder behandelde, lokaal gevorderde/gemetastaseerde, geprogrammeerde dood Ligand 1-geselecteerde niet-kleincellige longkanker
This study will monitor the safety of novel immunotherapy combinations in participants with Programmed death ligand-1 (PD L-1) high (Tumor cells [TC]/ Tumor proportion score [TPS] >= 50%), previously untreated, unresectable, locally advanced or metastatic non-small cell lung cancer (NSCLC). Drug name mentioned as Belrestotug, GSK4428859A, and EOS884448 are all interchangeable for the same compound. In the rest of the document, the drug will be referred to as Belrestotug.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
-
Buenos Aires, Argentinië, C1426ABP
- GSK Investigational Site
-
Cipoletti Rio Negro, Argentinië, R8324CVE
- GSK Investigational Site
-
Ciudad Autonoma de Buenos Aire, Argentinië, C1414DRK
- GSK Investigational Site
-
Ciudad Autonoma de Buenos Aire, Argentinië, C1426AGE
- GSK Investigational Site
-
Florida, Argentinië, 1602
- GSK Investigational Site
-
Mar del Plata, Argentinië, 7600
- GSK Investigational Site
-
San Juan, Argentinië, J5402DIL
- GSK Investigational Site
-
Santa Fe, Argentinië, 3000
- GSK Investigational Site
-
-
-
-
-
Wilrijk, België, 2650
- GSK Investigational Site
-
-
-
-
-
Barretos, Brazilië, 14784-400
- GSK Investigational Site
-
Porto Alegre, Brazilië, 90610-000
- GSK Investigational Site
-
São Paulo, Brazilië, 01246-000
- GSK Investigational Site
-
Vitória, Brazilië, 29043-260
- GSK Investigational Site
-
-
-
-
-
Berlin, Duitsland, 13125
- GSK Investigational Site
-
Heidelberg, Duitsland, 69126
- GSK Investigational Site
-
-
North Rhine-Westphalia
-
Essen, North Rhine-Westphalia, Duitsland, 45147
- GSK Investigational Site
-
-
Schleswig-Holstein
-
Großhansdorf, Schleswig-Holstein, Duitsland, 22927
- GSK Investigational Site
-
-
Thuringia
-
Jena, Thuringia, Duitsland, 07747
- GSK Investigational Site
-
-
-
-
-
Oulu, Finland, 90220
- GSK Investigational Site
-
Tampere, Finland, 33520
- GSK Investigational Site
-
Turku, Finland, 20520
- GSK Investigational Site
-
Vaasa, Finland, 65130
- GSK Investigational Site
-
-
-
-
-
Bordeaux, Frankrijk, 33076
- GSK Investigational Site
-
Caen, Frankrijk, 14033
- GSK Investigational Site
-
Marseille, Frankrijk, 13009
- GSK Investigational Site
-
Quimper, Frankrijk, 29107
- GSK Investigational Site
-
Strasbourg, Frankrijk, 67091
- GSK Investigational Site
-
-
-
-
-
Athens, Griekenland, 11528
- GSK Investigational Site
-
Pylaia Thessaloniki, Griekenland, 57001
- GSK Investigational Site
-
Thessaloniki, Griekenland, 54645
- GSK Investigational Site
-
-
Attica
-
Athens, Attica, Griekenland, 115 27
- GSK Investigational Site
-
Chaïdári, Attica, Griekenland, 124 62
- GSK Investigational Site
-
-
Central Macedonia
-
Thessaloniki, Central Macedonia, Griekenland, 570 10
- GSK Investigational Site
-
-
Thessaly
-
Larissa, Thessaly, Griekenland, 411 10
- GSK Investigational Site
-
-
-
-
-
Budapest, Hongarije, H-1121
- GSK Investigational Site
-
Gyöngyös, Hongarije, 3200
- GSK Investigational Site
-
Tatabánya, Hongarije, 2800
- GSK Investigational Site
-
-
-
-
-
Avellino, Italië, 83100
- GSK Investigational Site
-
Bergamo, Italië, 24125
- GSK Investigational Site
-
Pisa, Italië, 57124
- GSK Investigational Site
-
Verona, Italië, 37045
- GSK Investigational Site
-
-
GE
-
Genova, GE, Italië, 16132
- GSK Investigational Site
-
-
-
-
-
Chiba, Japan, 277-8577
- GSK Investigational Site
-
Fukuoka, Japan, 812-8582
- GSK Investigational Site
-
Hyōgo, Japan, 673-8558
- GSK Investigational Site
-
Kanagawa, Japan, 241-8515
- GSK Investigational Site
-
Osaka, Japan, 590-0197
- GSK Investigational Site
-
Saitama, Japan, 350-1298
- GSK Investigational Site
-
-
-
-
-
Guadajalara, Mexico, 44280
- GSK Investigational Site
-
San Luis Potosí City, Mexico, 78209
- GSK Investigational Site
-
-
-
-
-
Enschede, Nederland, 7512 KZ
- GSK Investigational Site
-
Groningen, Nederland, 9728 NZ
- GSK Investigational Site
-
Leeuwarden, Nederland, 8934 AD
- GSK Investigational Site
-
Utrecht, Nederland, 3543 AZ
- GSK Investigational Site
-
-
-
-
-
Lublin, Polen, 20-954
- GSK Investigational Site
-
Prabuty, Polen, 82-550
- GSK Investigational Site
-
Siedlce, Polen, 08-110
- GSK Investigational Site
-
-
-
-
-
Guimarães, Portugal, 4835-044
- GSK Investigational Site
-
Lisbon, Portugal, 1500-650
- GSK Investigational Site
-
Lisbon, Portugal, 1998-018
- GSK Investigational Site
-
Porto, Portugal, 4200-072
- GSK Investigational Site
-
Vila Nova de Gaia, Portugal, 4434-502
- GSK Investigational Site
-
-
-
-
-
Badajoz, Spanje, 06080
- GSK Investigational Site
-
Barcelona, Spanje, 08035
- GSK Investigational Site
-
Las Palmas de Gran Canar, Spanje, 35016
- GSK Investigational Site
-
Madrid, Spanje, 28041
- GSK Investigational Site
-
Madrid, Spanje, 28046
- GSK Investigational Site
-
Madrid, Spanje, 28027
- GSK Investigational Site
-
Málaga, Spanje, 29010
- GSK Investigational Site
-
PamplonaNavarra, Spanje, 28027
- GSK Investigational Site
-
Valencia, Spanje, 46026
- GSK Investigational Site
-
Valencia, Spanje, 46009
- GSK Investigational Site
-
-
Barcelona
-
Badalona, Barcelona, Spanje, 08916
- GSK Investigational Site
-
L'Hospitalet de Llobregat, Barcelona, Spanje, 08907
- GSK Investigational Site
-
-
-
-
-
Bangkok, Thailand, 10210
- GSK Investigational Site
-
Chiang Mai, Thailand, 50200
- GSK Investigational Site
-
Kho Hong Hat Yai, Thailand, 90110
- GSK Investigational Site
-
Khon Kaen, Thailand, 40002
- GSK Investigational Site
-
Pathum Thani, Thailand, 12120
- GSK Investigational Site
-
-
-
-
-
Ankara, Turkije (Türkiye), 06800
- GSK Investigational Site
-
Ankara, Turkije (Türkiye), 06680
- GSK Investigational Site
-
Antalya, Turkije (Türkiye), 07070
- GSK Investigational Site
-
Istanbul, Turkije (Türkiye), 34214
- GSK Investigational Site
-
-
Atakum
-
Samsun, Atakum, Turkije (Türkiye), 55200
- GSK Investigational Site
-
-
-
-
-
Middlesbrough, Verenigd Koninkrijk, TS4 3BW
- GSK Investigational Site
-
Wolverhampton, Verenigd Koninkrijk, WV10 0QP
- GSK Investigational Site
-
-
Middlesex
-
Northwood, Middlesex, Verenigd Koninkrijk, HA6 2RN
- GSK Investigational Site
-
-
-
-
-
Abu Dhabi, Verenigde Arabische Emiraten
- GSK Investigational Site
-
Abu Dhabi, Verenigde Arabische Emiraten, 51900
- GSK Investigational Site
-
-
-
-
Florida
-
Plantation, Florida, Verenigde Staten, 33322-5426
- GSK Investigational Site
-
-
New Mexico
-
Albuquerque, New Mexico, Verenigde Staten, 87131
- GSK Investigational Site
-
-
Tennessee
-
Chattanooga, Tennessee, Verenigde Staten, 37404
- GSK Investigational Site
-
-
West Virginia
-
Morgantown, West Virginia, Verenigde Staten, 26506
- GSK Investigational Site
-
-
-
-
-
Incheon, Zuid -Korea, 21565
- GSK Investigational Site
-
Seoul, Zuid -Korea, 03080
- GSK Investigational Site
-
Seoul, Zuid -Korea, 03722
- GSK Investigational Site
-
Suwon Gyeonggi-do, Zuid -Korea, 442-723
- GSK Investigational Site
-
-
-
-
-
Cape Town, Zuid-Afrika, 7570
- GSK Investigational Site
-
Parktown, Zuid-Afrika, 2193
- GSK Investigational Site
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Histologically or cytologically confirmed diagnosis of locally advanced unresectable NSCLC not eligible for curative surgery and/or definitive radiotherapy with or without chemotherapy or metastatic NSCLC (squamous or non squamous)
- No prior systemic therapy for their locally advanced or metastatic NSCLC
- Provides a fresh tumor tissue sample or archival sample collected within 2 years prior to screening
- PD-L1-high (TC/TPS >= 50%) tumor
- Measurable disease based on RECIST 1.1, as determined by the investigator
- Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1
- Adequate Baseline organ function
- Female participants of childbearing potential must use adequate contraception
Exclusion Criteria:
- Has NSCLC with a tumor that harbors any of the following molecular alterations: EGFR and /or ALK translocations mutations that are sensitive to available targeted inhibitor therapy, Any other known genomic aberrations or oncogenic driver mutations for which a locally approved targeted therapy is available for first-line treatment of locally advanced or metastatic NSCLC.
- Had major surgery within 4 weeks or lung radiation of >30 Gy therapy within 6 months prior to the first dose of study intervention
- Received prior therapy with any immune checkpoint inhibitors
- Never smoked, defined as smoking <100 tobacco cigarettes in a lifetime
- Has an invasive malignancy or history of invasive malignancy other than the disease under study within the last 5 years (clinical exceptions apply as per protocol)
- Symptomatic, untreated, or actively progressing, brain metastases or any leptomeningeal disease (regardless of symptomatology, treatment status, or stability)
- Autoimmune disease or syndrome that required systemic treatment within the past 2 years
- Receiving systemic steroid therapy <= 3 days prior to first dose of study intervention or any form of immunosuppressive medication
- Received any live vaccine <= 30 days prior to first dose of study intervention
- Any history of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis
- History or evidence of cardiac abnormalities
- Current unstable liver or biliary disease
- Severe infection within 4 weeks prior to the first dose of study intervention
- Positive for tuberculosis, human immunodeficiency virus (HIV) infection, hepatitis B surface antigen, or hepatitis C
- Has advanced, symptomatic, or visceral spread and is considered to be at imminent risk of life-threatening complications (including, but not limited to, massive uncontrolled effusions [e.g., pleural, pericardial, peritoneal])
- Is currently participating in or has participated in a study of an investigational therapy within 4 weeks prior to the first dose of study intervention
- Has a history of allogeneic tissue/stem cell transplant or solid organ transplant
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Actieve vergelijker: Pembrolizumab Monotherapy
Participants will be administered with pembrolizumab as monotherapy in a fixed dose. |
Pembrolizumab will be administered. |
|
Experimenteel: Dostarlimab Monotherapy
Participants will be administered with dostarlimab as monotherapy in a fixed dose. |
Dostarlimab will be administered
Andere namen:
|
|
Experimenteel: Substudy 1A
Participants will be administered with dostarlimab in a fixed dose followed by belrestotug in a fixed dose (Dose A). |
Belrestotug will be administered.
Andere namen:
Dostarlimab will be administered
Andere namen:
|
|
Experimenteel: Substudy 1B
Participants will be administered with dostarlimab in a fixed dose followed by belrestotug in a fixed dose (Dose B). |
Belrestotug will be administered.
Andere namen:
Dostarlimab will be administered
Andere namen:
|
|
Experimenteel: Substudy 1C
Participants will be administered with dostarlimab in a fixed dose followed by belrestotug in a fixed dose (Dose C). |
Belrestotug will be administered.
Andere namen:
Dostarlimab will be administered
Andere namen:
|
|
Experimenteel: Substudy 2A
Participants will be administered with dostarlimab, fixed dose belrestotug, and fixed dose nelistotug |
Belrestotug will be administered.
Andere namen:
Nelistotug will be administered.
Andere namen:
Dostarlimab will be administered
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Aantal deelnemers met behandeling opkomende bijwerkingen (Teaes) en ernstige bijwerkingen (SAES)
Tijdsspanne: Tot 228 weken
|
Tot 228 weken
|
|
Aantal deelnemers met TEEAS of SAE's die leidt tot dosisaanpassingen of behandeling van behandeling
Tijdsspanne: Tot 228 weken
|
Tot 228 weken
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Studie directeur: GSK Clinical Trials, GlaxoSmithKline
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 213824
- 2021-005115-32 (EudraCT-nummer)
- GALAXIES LUNG-201 (Andere identificatie: Study Identifier)
- 2023 (Subsidie/contract van de Amerikaanse NIH)
- 2023-505057-40-00 (Register-ID: CTIS (EU))
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/
IPD-tijdsbestek voor delen
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
IPD-toegangscriteria voor delen
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
- ICF
- MVO
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .